Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial.
scientific article published on 17 July 2017
Author/s
author: Georgina V. Long, Jonathan Cebon, Alexander M Menzies, Richard F. Kefford, Benjamin Y Kong, Antoni Ribas, F Stephen Hodi, John F Thompson, Alexander D Guminski, Matteo Carlino, Catriona M McNeil, Michael B Atkins, Nageatte Ibrahim
Work details
Copyright status
Copyright status information is not available for this work. The copyright status depends on the jurisdiction, the author's date of death and the date the work was created or published.
To learn more about copyright terms in different countries, visit the countries and terms page.